Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma

Shigesawa, Taku; Suda, Goki; Kimura, Megumi; Shimazaki, Tomoe; Maehara, Osamu; Yamada, Ren; Kitagataya, Takashi; Suzuki, Kazuharu; Nakamura, Akihisa; Ohara, Masatsugu; Umemura, Machiko; Kawagishi, Naoki; Nakai, Masato; Sho, Takuya; Natsuizaka, Mitsuteru; Morikawa, Kenichi; Ogawa, Koji; Sakamoto, Naoya

Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma

Shigesawa, Taku; Suda, Goki; Kimura, Megumi et al.

JGH open, 2020, 4(5), 880-888

Permalink : https://hdl.handle.net/2115/79632

このアイテムのアクセス数:689件（2026-08-19 17:26 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
https://doi.org/10.1002/jgh3.12339			19

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/79632
タイトル	Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma
著者	Shigesawa, Taku ; Suda, Goki ; Kimura, Megumi ; Shimazaki, Tomoe ; Maehara, Osamu ; Yamada, Ren ; Kitagataya, Takashi ; Suzuki, Kazuharu ; Nakamura, Akihisa ; Ohara, Masatsugu ; Umemura, Machiko ; Kawagishi, Naoki ; Nakai, Masato ; Sho, Takuya ; Natsuizaka, Mitsuteru ; Morikawa, Kenichi ; Ogawa, Koji ; Sakamoto, Naoya
著者名 Shigesawa, Taku
e-Rad_Researcher 20447460 著者名 Suda, Goki
著者名 Kimura, Megumi
著者名 Shimazaki, Tomoe
著者名 Maehara, Osamu
著者名 Yamada, Ren
著者名 Kitagataya, Takashi
著者名 Suzuki, Kazuharu
著者名 Nakamura, Akihisa
著者名 Ohara, Masatsugu
著者名 Umemura, Machiko
著者名 Kawagishi, Naoki
著者名 Nakai, Masato
著者名 Sho, Takuya
e-Rad_Researcher 80642446 著者名 Natsuizaka, Mitsuteru
著者名 Morikawa, Kenichi
e-Rad_Researcher 20735188 著者名 Ogawa, Koji
e-Rad_Researcher 10334418 著者名 Sakamoto, Naoya
言語	英語
キーワード	angiopoietin-2
	fibroblast growth factor 19
	hepatocellular carcinoma
	sorafenib
	treatment outcome
発行日	2020-10
出版者	John Wiley & Sons
収録物名	JGH open
巻(号)	4(5)
ページ	880-888
抄録	Background Sorafenib and lenvatinib are first-line systemic therapies for unresectable hepatocellular carcinoma (HCC). However, the criteria for their selection remain unclear. Methods We identified patients with unresectable HCC who were treated with sorafenib or lenvatinib between August 2009 and January 2019 at the Hokkaido University Hospital. Patients who continued treatment for >2 months, underwent evaluation by computed tomography every 2-3 months, and had complete clinical data were included. Responders were patients with objective response (OR) for lenvatinib and patients with stable disease (SD) exceeding 6 months (long-SD) or OR for sorafenib. The predictive factors for treatment response, including fibroblast growth factor (FGF)19 and 21, angiopoietin 2 (ANG2), hepatocyte growth factor, and vascular endothelial growth factor, were evaluated. Results Overall, 27 and 29 patients treated with lenvatinib and sorafenib, respectively, were included. The responders for lenvatinib and sorafenib were 63% (17/27) and 38% (11/29), respectively. No significant predictive factors for treatment response were identified in patients treated with sorafenib. However, baseline serum FGF19 and ANG2 levels were significantly associated with treatment response to lenvatinib. All (9/9) patients with low baseline ANG2 and FGF19 levels who received lenvatinib achieved OR. Conversely, the OR was low (13%; 1/9) in patients with high baseline ANG2 and FGF19 levels. Responder rate was 40% (2/5) in patients with high baseline ANG2 and FGF19 levels who received sorafenib. Conclusion This study is, to our knowledge, the first to demonstrate that baseline ANG2 and FGF19 levels may aid in selecting optimal systemic therapy for patients with unresectable HCC.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
権利情報	Creative Commons Attribution 4.0 International
PISSN	2397-9070
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1002/jgh3.12339